Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Advocates claim Gilead and others unfairly limited competition for HIV combination pills.
Researchers have called for revised treatment guidelines to address the higher risk of fracture in the HIV population.
Researchers at George Washington University take a look.
The latest revision recognizes the importance of treatment as prevention.
The integrase inhibitor–based HIV regimen was compared with dolutegravir-based regimens.
This finding from a study of people switching from TDF to TAF for HIV treatment may also have implications for those on PrEP.
The newer tenofovir formulation can raise cholesterol and triglyceride levels, but these changes are reversible.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.
Currently, Gilead Sciences’ HIV regimen is not approved to treat drug-resistant virus.
The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.
This held true even among those with resistance to nucleoside/nucleotide reverse transcriptase inhibitors.
More high-quality evidence is needed to determine how this class of HIV medications may affect weight gain.
Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.